BioSpace News Archive

Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren’s Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren’s contracture (DC).

POINT Biopharma Global Inc. today announced a collaboration on the development of a global 212 Pb radioisotope and radioligand supply chain and drug manufacturing network to specifically support the clinical development and commercialization of 212Pb-labeled radioligands by each company.

New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions.

Agile Therapeutics, Inc. today announced that Twirla will become available to MMCAP Infuse Members effective July 1, 2023.

Cidara Therapeutics, Inc. announced it has joined the broad market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226).

Vertex Pharmaceuticals Incorporated and Lonza announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.

Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced updated positive interim data from its ongoing Phase 1/2 clinical trial of the Cell Pouch System in patients with type 1 diabetes (T1D) and severe hypoglycemia unawareness.

BioAtla, Inc. announced that the Company has been added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. markets open on June 26, 2023, as part of the 2023 Russell indexes reconstitution in the broad-market Russell 3000® Index.

LianBio (Nasdaq: LIAN) today announced that CAMZYOS® (mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the Singapore Health Sciences Authority.